Summary Basis for Regulatory Action

First Page		Document Content
Orphan drugs Transfusion medicine Idiopathic thrombocytopenic purpura Romiplostim Thrombocytopenia Intravenous immunoglobulin Rho(D) immune globulin Eltrombopag Platelet Medicine Biology Blood		Summary Basis for Regulatory Action Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 331,47 KB Share Document on Facebook

	A study of the Implementation of Romiplostim & Eltrombopag in the NHS in England Lisa 1 Cooper DocID: 1fRWP - View Document
	Eltrombopag is effectief bij therapieresistente aplastische anemie Harry R. Koene Ned Tijdschr Geneeskd. 2012;156:A5397 Auteursinformatie Waarom dit onderzoek? Aplastische anemie is een zeldzame ziekte die gekenmerkt wor DocID: 1aL75 - View Document
	The ITP Support Association ___________________________________________ DocID: 16RfE - View Document
	Scottish Medicines Consortium Minutes of the SMC Meeting held on Tuesday 05 November 2013 Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP Present: DocID: 11l9H - View Document
	SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of DocID: Zya6 - View Document